Boston Scientific Closes Symetis Acquisition
May 16, 2017—Boston Scientific Corporation announced the close of its acquisition of Symetis SA, a privately held Swiss structural heart company focused on transcatheter aortic valve replacement (TAVR) devices. The companies announced a definitive agreement on March 30, 2017, for Boston Scientific to acquire the Symetis business for $435 million in cash. Symetis will become part of the Boston Scientific Interventional Cardiology division.
With the completion of the acquisition, Boston Scientific will immediately begin selling the Acurate TA transapical valve system and the Acurate neo/TF transfemoral valve system in Europe and other geographies outside of the United States. The Acurate TAVR devices are designed to treat patients with severe and symptomatic aortic valve stenosis who are considered high risk for surgical valve replacement.
Results for the Acurate neo/TF valve in the SAVI-TF Registry were presented as a late breaking clinical trial at the EuroPCR 2017 conference in Paris, France. This European postmarket study assessed the primary endpoint of all-cause mortality at 30 days, as well as the Valve Academic Research Consortium's VARC-2 clinical endpoints through 1 year in 1,000 patients.
Boston Scientific expects to continue the development of the Acurate neo/AS next-generation valve system that is currently in a clinical trial intended to support a future application for European CE Mark approval.
advertisement
Featured Video
Evolut™ PRO System
Sponsored by Medtronic
Related Articles
Current Status and Expectations for Low-Risk TAVI Trials
An expert opinion on how current clinical trials will impact the future of TAVI procedures in low-risk patients.
With Marc Dweck, MD, PhD
East Meets West: Emerging Transcatheter Aortic Valve Technologies
Emerging valve systems and iterative technologies from around the world and how they could shape global practice going forward.
By Federico Mercanti, MD; Zhen-Gang Zhao, MD; Antoinette Neylon, MD, BCh; Mao Chen, MD, PhD; and Darren Mylotte, MD, BCh
Top 5 Articles From April 2017
Current TAVR Devices
Technical characteristics and evidence to date for FDA- and CE Mark-approved valves.
By Denise Todaro, MD; Andrea Picci, MD; and Marco Barbanti, MD
Aortic Valves: What’s Coming?
Devices in early clinical development, including devices with early human experience and those originating from China.
By Thomas Modine, MD, PhD, MBA; Darren Mylotte, MD; and Nicolo Piazza, MD, PhD
Making the Most of CT in TAVR Planning
From clinical research to standard-of-care procedural planning.
By Hasan Jilaihawi, MD
New Insights From the STS/ACC TVT Registry
What these ongoing data tell us about TAVR and future areas of interest.
By Frederick L. Grover, MD; and David R. Holmes Jr, MD
Top 5 from EVToday's Current Issue
Endovascular Treatment of Pelvic Congestion Syndrome
PCS remains underdiagnosed and undertreated, but recognizing this condition and providing endovascular treatment can benefit women with chronic pelvic pain.
By Andrew C. Picel, MD; and Anne C. Roberts, MD
A US Perspective: PAE: Is It Ready for Prime Time?
A commentary on the benefits of prostatic artery embolization, opportunities for training, and challenges to widespread adoption.
By Sandeep Bagla, MD
Splenic Artery Embolization: Proximal or Distal?
A review of when proximal or distal embolization should be used, optimal technique, and results of studies evaluating outcomes.
